A phase I/IIa study of zona pellucida antigens (ZP) in female patients with metastasised ovarian cancer

Trial Profile

A phase I/IIa study of zona pellucida antigens (ZP) in female patients with metastasised ovarian cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 31 Oct 2014

At a glance

  • Drugs Zona pellucida vaccine (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2014 New trial record
    • 27 Oct 2014 Pantarhei Bioscience in collaboration with HRA Pharma plans to initiate this trial by 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top